The bleeding diathesis in patients with hereditary haemorrhagic telangiectasia is not due to impaired platelet function

被引:0
|
作者
Lyster, Anne Lorup [1 ,2 ,3 ,4 ,8 ]
Biorn, Signe Hedengran [1 ,2 ]
Kjeldsen, Anette Drohse [2 ,4 ,6 ,7 ]
Nielsen, Christian [5 ]
Lange, Bibi [4 ]
Fialla, Annette Dam [2 ,3 ,6 ,7 ]
Vinholt, Pernille Just [1 ,2 ]
机构
[1] Odense Univ Hosp, Dept Clin Biochem, Winslows Vej 4, DK-5000 Odense C, Denmark
[2] Univ Southern Denmark SDU, Dept Clin Res, Campusvej 55, DK-5230 Odense M, Denmark
[3] Odense Univ Hosp, Dept Gastroenterol, JB Winslows Vej 4, DK-5000 Odense C, Denmark
[4] Odense Univ Hosp, Dept Oto Rhino Laryngol, JB Winslows Vej 4, DK-5000 Odense C, Denmark
[5] Odense Univ Hosp, Dept Clin Immunol, JB Winslows Vej 4, DK-5000 Odense C, Denmark
[6] VASCERN European Reference Network Rare Multisyst, DK-5000 Paris, France
[7] HHT Ctr Odense Univ Hosp, DK-5000 Odense C, Denmark
[8] Patient Data Explorat Network, OPEN, JB Winslows Vej 9A, Third Floor, DK-5000 Odense C, Denmark
关键词
Hereditary haemorrhagic telangiectasia; Platelet function; Bleeding; Primary haemostasis; AGGREGATION;
D O I
10.1186/s13023-023-02968-z
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
BackgroundPatients with the rare disease; Hereditary haemorrhagic telangiectasia (HHT) often bleed from telangiectatic lesions in mucosal surfaces. Studies suggest that impaired platelet function may also play a role in their bleeding tendency. The aim of the present study was to investigate whether HHT-patients with epistaxis have impaired platelet function.MethodWe conducted a case-control study based on a sample size calculation and included 22 HHT-patients (inclusion criteria: epistaxis severity score >= 4, no intake of medicine affecting platelet function the last 5 days, HHT-type 1 or 2, age >= 18 years) and 20 controls. We assessed the platelet function with standard haemostasis parameters, flow cytometry (platelet function and micro aggregation), rotational thromboelastometry and Platelet Function Analyzer 200.ResultsWe found no significant difference in mean platelet volume and immature platelet fraction and no difference in platelet activation as measured by exposure of CD62P, CD63P and PAC1 binding. Nor did we find a significant difference in platelet aggregation response in HHT-patients compared with the control group for all agonists (thrombin receptor activating peptide, adenosine diphosphate and collagen-related peptide). The PFA-200 analysis was without difference between the two groups and thromboelastometry showed no impairment of global haemostasis.ConclusionReduced platelet function is unlikely to contribute to the frequent and long bleeding episodes that HHT-patients suffer from. We propose that further studies should focus on whether patients with HHT have hypercoagulability.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] The bleeding diathesis in patients with hereditary haemorrhagic telangiectasia is not due to impaired platelet function
    Anne Lørup Lyster
    Signe Hedengran Biørn
    Anette Drøhse Kjeldsen
    Christian Nielsen
    Bibi Lange
    Annette Dam Fialla
    Pernille Just Vinholt
    Orphanet Journal of Rare Diseases, 18
  • [2] BEVACIZUMAB AS TREATMENT OF BLEEDING IN PATIENTS WITH HEREDITARY HAEMORRHAGIC TELANGIECTASIA (HHT)
    Kjeldsen, Jens
    Fialla, Annette D.
    Rosenberg, Tine
    Kjeldsen, Anette D.
    GASTROENTEROLOGY, 2018, 154 (06) : S701 - S702
  • [3] MEK 1 inhibition and bleeding in hereditary haemorrhagic telangiectasia
    Shovlin, Claire L.
    Patel, Dilip
    Bielowka, Adrianna
    Ledermann, Jonathan A.
    Modarresi, Atieh
    Bernabeu-Herrero, Maria E.
    Aldred, Micheala A.
    Alsafi, Ali
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (01) : 361 - 365
  • [4] Re-treating bleeding hereditary haemorrhagic telangiectasia with bevacizumab
    Ho, Gwo Yaw
    Zhong, Edward
    Chern, Boris
    MEDICAL JOURNAL OF AUSTRALIA, 2013, 199 (10) : 658 - 658
  • [6] Molecular defects in rare bleeding disorders: Hereditary haemorrhagic telangiectasia
    Shovlin, CL
    THROMBOSIS AND HAEMOSTASIS, 1997, 78 (01) : 145 - 150
  • [7] Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia
    Al-Samkari, H.
    Kritharis, A.
    Rodriguez-Lopez, J. M.
    Kuter, D. J.
    JOURNAL OF INTERNAL MEDICINE, 2019, 285 (02) : 223 - 231
  • [8] Life expectancy in patients with hereditary haemorrhagic telangiectasia
    Sabbà, C
    Pasculli, G
    Suppressa, P
    D'Ovidio, F
    Lenato, GM
    Resta, F
    Assennato, G
    Guanti, G
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2006, 99 (05) : 327 - 334
  • [9] How to manage patients with hereditary haemorrhagic telangiectasia
    Geisthoff, Urban W.
    Nguyen, Ha-Long
    Roeth, Alexander
    Seyfert, Ulrich
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 171 (04) : 443 - 452
  • [10] Cerebral screening in patients with hereditary haemorrhagic telangiectasia
    Jackson, A.
    Briggs, T. A.
    Clayton-Smith, J.
    INTERNAL MEDICINE JOURNAL, 2014, 44 (10) : 1047 - 1047